Regulus Therapeutics Inc. [NASDAQ: RGLS] stock went on an upward path that rose over 13.04% on Friday, amounting to a one-week price increase of more than 4.84%. The company report on March 6, 2021 that Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021.
A webcast of the on-demand presentation will be available beginning Tuesday, March 9, 2021 through the investor relations section of the Company’s website at www.regulusrx.com. A replay of the webcast will be archived for 30 days following the presentation date.
Over the last 12 months, RGLS stock rose by 80.18%. The one-year Regulus Therapeutics Inc. stock forecast points to a potential upside of 2.26. The average equity rating for RGLS stock is currently 2.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $45.01 million, with 38.14 million shares outstanding and 36.65 million shares in the current float. Compared to the average trading volume of 2.70M shares, RGLS stock reached a trading volume of 2072033 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Regulus Therapeutics Inc. [RGLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RGLS shares is $1.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RGLS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR Inc. have made an estimate for Regulus Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2018. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on January 05, 2018, representing the official price target for Regulus Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Chardan Capital Markets kept a Buy rating on RGLS stock. On March 06, 2017, analysts decreased their price target for RGLS shares from 8 to 6.
The Average True Range (ATR) for Regulus Therapeutics Inc. is set at 0.20, with the Price to Sales ratio for RGLS stock in the period of the last 12 months amounting to 9.00. The Price to Book ratio for the last quarter was 6.50, with the Price to Cash per share for the same quarter was set at 0.51.
RGLS Stock Performance Analysis:
Regulus Therapeutics Inc. [RGLS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.84. With this latest performance, RGLS shares dropped by -10.96% in over the last four-week period, additionally plugging by 173.51% over the last 6 months – not to mention a rise of 80.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RGLS stock in for the last two-week period is set at 44.67, with the RSI for the last a single of trading hit 42.57, and the three-weeks RSI is set at 47.09 for Regulus Therapeutics Inc. [RGLS]. The present Moving Average for the last 50 days of trading for this stock 1.4108, while it was recorded at 1.2820 for the last single week of trading, and 0.8667 for the last 200 days.
Insight into Regulus Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Regulus Therapeutics Inc. [RGLS] shares currently have an operating margin of -246.40. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13.
Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Additionally, RGLS Total Debt to Total Capital is recorded at 43.36, with Total Debt to Total Assets ending up at 36.42. Long-Term Debt to Equity for the company is recorded at 0.28, with the Long-Term Debt to Total Capital now at 0.16.
Reflecting on the efficiency of the workforce at the company, Regulus Therapeutics Inc. [RGLS] managed to generate an average of -$885,333 per employee. Receivables Turnover for the company is 11.71 with a Total Asset Turnover recorded at a value of 0.20.Regulus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
RGLS Stock EPS
With the latest financial reports released by the company, Regulus Therapeutics Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc. go to 39.60%.
Regulus Therapeutics Inc. [RGLS] Insider Position Details
There are presently around $24 million, or 75.20% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 6,451,056, which is approximately 214.309% of the company’s market cap and around 8.60% of the total institutional ownership; BVF INC/IL, holding 3,376,207 shares of the stock with an approximate value of $4.39 million in RGLS stocks shares; and POINT72 ASSET MANAGEMENT, L.P., currently with $4.18 million in RGLS stock with ownership of nearly New of the company’s market capitalization.
Positions in Regulus Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 18 institutional holders increased their position in Regulus Therapeutics Inc. [NASDAQ:RGLS] by around 10,914,435 shares. Additionally, 10 investors decreased positions by around 317,184 shares, while 8 investors held positions by with 7,180,498 shares. The mentioned changes placed institutional holdings at 18,412,117 shares, according to the latest SEC report filing. RGLS stock had 10 new institutional investments in for a total of 5,936,505 shares, while 7 institutional investors sold positions of 289,410 shares during the same period.